Human embryonic stem cell-conditioned medium induces cell cycle arrest in HL60 cells by unknown soluble factor(s) in vitro
More details
Hide details
Department of Anatomical Sciences, Faculty of Medicine, Kurdistan University of Medical Sciences, Sanandaj, Iran
Department of Immunology and Hematology, Faculty of Medicine, Kurdistan University of Medical Sciences, Sanandaj, Iran
Department of Anatomy and Neuroscience, Shahrekord University of Medical Sciences, Shahrekord, Iran
Department of Pharmaceutical Biotechnology, Faculty of Pharmacy, Lorestan University of Medical Sciences, Khorramabad, Iran
Department of Biostatistics, Faculty of Medicine, Kurdistan University of Medical Sciences, Sanandaj, Iran
Department of Anatomy, Faculty of Medicine, Kurdistan University of Medical Sciences, Sanandaj, Iran
Mohammad Jafar Rezaie   

Department of Anatomy, Faculty of Medicine, Kurdistan University of Medical Sciences, Sanandaj, Iran. Tel.: +988733664653, Fax: +988716664663.
Submission date: 2017-04-21
Acceptance date: 2017-06-13
Online publication date: 2018-06-29
Publication date: 2019-11-18
Pol. Ann. Med. 2018;25(2):224–230
Acute myeloid leukemia (AML) is a type of cancer that affects the blood and bone marrow, characterized by the rapid growth of abnormal white blood cells.

The aim of the present study was to evaluate the inhibitory effect of human embryonic stem cell – conditioned medium (hESC-CM) on the proliferation of human leukemic HL-60 cells.

Material and methods:
We measured proliferation of myeloid leukemia cell by XTT assay. Also cell cycle and apoptosis was measured by flow cytometry after the cells stained.

Results and discussion:
Our experiment indicated that the human embryonic stem cells conditioned medium has anti-proliferative effects on the progression of HL60 cell. HL60 cells were treated with conditioned medium; the results of the flow cytometry demonstrate that hESC-CM was capable of increasing apoptosis of HL60 cells and inhibit the cell cycle progression.

Our results show that Human embryonic stem cell conditioned medium contain factors that are able to inhibit the growth and inducing apoptosis of HL60 cells, which may represent a novel therapeutic approach for leukemia. However, further investigation is needed to identify the role of these factors.

This research was supported by Kurdistan University of Medical Sciences. (IR.MUK.REC.1395.25). The authors would like to thank the staff of the Cellular and Molecular Research Center, Kurdistan University of Medical Sciences, for their kind cooperation. Moreover, we would like to appreciate the kindness of Dr. Abas Ahmadi for his assistance.
None declared.
Xia J, Chen SF, Lv YP, Lu LN, Hu WX, Zhou YL. ZGDHu-1 induces G2/M phase arrest and apoptosis in Kasumi-1 cells. Mol Med Rep. 2015;11(5):3398–3404.
Wei S, Wang Y, Chai Q, Fang Q, Zhang Y, Wang J. In vivo and in vitro effects of heme oxygenase-1 silencing on the survival of acute myelocytic leukemia-M2 cells. Expe Ther Med. 2015;9(3):931–940.
Gordeeva O, Nikonova T. Development of experimental tumors formed by mouse and human embryonic stem and teratocarcinoma cells after subcutaneous and intraperitoneal transplantations into immunodeficient and immunocompetent mice. Cell Transplant. 2013;22(10):1901–1914.
Ben-David U, Benvenisty N. The tumorigenicity of human embryonic and induced pluripotent stem cells. Nat Rev Cancer. 2011;11(4):268–277.
Herberts CA, Kwa MS, Hermsen HP. Risk factors in the development of stem cell therapy. J Transl Med. 2011;9:1.
Bhang SH, Lee S, Shin J-Y, Lee T-J, Jang H-K, Kim B-S. Efficacious and clinically relevant conditioned medium of human adipose-derived stem cells for therapeutic angiogenesis. Mol Ther. 2014;22(4):862–872.
Pawitan JA. Prospect of stem cell conditioned medium in regenerative medicine. BioMed Res Int. 2014;2014:1–5.
Díez-Torre A, Andrade R, Eguizábal C, et al. Reprogramming of melanoma cells by embryonic microenvironments. Int J Dev Biol. 2009;53(8–10):1563–1568.
Dong W, Du J, Shen H, et al. Administration of embryonic stem cells generates effective antitumor immunity in mice with minor and heavy tumor load. Cancer Immunol Immunother. 2010;59(11):1697–1705.
Dong W, Qiu C, Shen H, Liu Q, Du J. Antitumor effect of embryonic stem cells in a non-small cell lung cancer model: antitumor factors and immune responses. Int J Med Sci. 2013;10(10):1314.
Li Y, Zeng H, Xu RH, Liu B, Li Z. Vaccination with human pluripotent stem cells generates a broad spectrum of immunological and clinical responses against colon cancer. Stem Cells. 2009;27(12):3103–3111.
Mocan T, Iancu C. Effective colon cancer prophylaxis in mice using embryonic stem cells and carbon nanotubes. Int J Nanomedicine. 2011;6:1945–1954.
Raof NA, Raja WK, Castracane J, Xie Y. Bioengineering embryonic stem cell microenvironments for exploring inhibitory effects on metastatic breast cancer cells. Biomaterials. 2011;32(17):4130–4139.
Kulesa PM, Kasemeier-Kulesa JC, Teddy JM, et al. Reprogramming metastatic melanoma cells to assume a neural crest cell-like phenotype in an embryonic microenvironment. Proc Natal Acad Sci. USA. 2006;103(10):3752–3757.
Lee LM, Seftor EA, Bonde G, Cornell RA, Hendrix MJ. The fate of human malignant melanoma cells transplanted into zebrafish embryos: assessment of migration and cell division in the absence of tumor formation. Dev Dynam. 2005;233(4):1560–1570.
Giuffrida D, Rogers I, Nagy A, Calogero A, Brown T, Casper R. Human embryonic stem cells secrete soluble factors that inhibit cancer cell growth. Cell Prolif. 2009;42(6):788–798.
Raof NA, Mooney BM, Xie Y. Bioengineering embryonic stem cell microenvironments for the study of breast cancer. Int J Mol Sci. 2011;12(11):7662–7691.
Biava PM, Basevi M, Biggiero L, Borgonovo A, Borgonovo E, Burigana F. Cancer cell reprogramming: stem cell differentiation stage factors and an agent based model to optimize cancer treatment. Curr Pharm Biotechnol. 2011;12(2):231–242.
Moon SY, Park YB, Kim D-S, Oh SK, Kim D-W. Generation, culture, and differentiation of human embryonic stem cells for therapeutic applications. Mol Ther. 2006;13(1):5–14.
Kim MO, Kim SH, Oi N, et al. Embryonic stem-cell-preconditioned microenvironment induces loss of cancer cell properties in human melanoma cells. Pigment Cell Melanoma Res. 2011;24(5):922–931.
Hughes C, Radan L, Chang WY, et al. Mass spectrometry–based proteomic analysis of the matrix microenvironment in pluripotent stem cell culture. Mol Cell Proteomics. 2012;11(12):1924–1936.
Dürr M, Harder F, Merkel A, Bug G, Henschler R, Müller AM. Chimaerism and erythroid marker expression after microinjection of human acute myeloid leukaemia cells into murine blastocysts. Oncogene. 2003;22(57):9185–9191.
Mohammadi M, Jaafari MR, Mirzaei HR, Mirzaei H. Mesenchymal stem cell: a new horizon in cancer gene therapy. Cancer Gene Ther. 2016;23(9):285–286.
Lin HD, Fong CY, Biswas A, Choolani M, Bongso A. Human umbilical cord Wharton’s jelly stem cell conditioned medium induces tumoricidal effects on lymphoma cells through hydrogen peroxide mediation. J Cell Biochem. 2016;117(9):2045–255.
Zhu Y, Sun Z, Han Q, et al. Human mesenchymal stem cells inhibit cancer cell proliferation by secreting DKK-1. Leukemia. 2009;23(5):925–933.
Yulyana Y, Ho IA, Sia KC, et al. Paracrine factors of human fetal MSCs inhibit liver cancer growth through reduced activation of IGF-1R/PI3K/Akt Signaling. Mol Ther. 2015;23(4):746–756.
Postovit L-M, Margaryan NV, Seftor EA, et al. Human embryonic stem cell microenvironment suppresses the tumorigenic phenotype of aggressive cancer cells. Proc Natal Acad Sci. 2008;105(11):4329–4334.
Golias C, Charalabopoulos A, Charalabopoulos K. Cell proliferation and cell cycle control: a mini review. Int J Clin Pract. 2004;58(12):1134–1141.
Cavallari C, Fonsato V, Herrera M, Bruno S, Tetta C, Camussi G. Role of Lefty in the anti tumor activity of human adult liver stem cells. Oncogene. 2013;32:819–826.
Lee JH, Park CH, Chun KH, Hong SS. Effect of adipose-derived stem cell-conditioned medium on the proliferation and migration of B16 melanoma cells. Oncol Lett. 2015;10(2):730–736.